Commit To Purchase Olema Pharmaceuticals At $16, Earn 40.4% Annualized Using Options

Selling the April 2026 $16 put on Olema Pharmaceuticals (OLMA) nets a premium that equates to a 40.4% annualized return, but only converts into share ownership if OLMA falls about 22.6% to the $16 strike—resulting in an effective cost basis of $13.40 per share after the $2.60 premium (before commissions); the trade therefore offers income but not upside participation. With OLMA trading at $20.88 and trailing 12‑month volatility of 123%, put sellers face meaningful downside risk and should weigh that volatility and fundamental outlook before writing the contract. Separately, mid‑afternoon S&P options flow showed a put:call ratio of 0.72 versus a long‑term median of 0.65, signaling somewhat elevated put buying in the market.

Analysis

The article evaluates selling the April 2026 $16 put on Olema Pharmaceuticals (OLMA), noting the contract nets a premium that equates to a 40.4% annualized return while OLMA trades at $20.88. Assignment would occur only if shares fall roughly 22.6% to the $16 strike, producing an effective cost basis of $13.40 per share after the $2.60 premium (before commissions), and the seller otherwise simply keeps the premium without upside participation.

Trailing-12‑month volatility for OLMA is cited at 123% (using the last 250 trading days and today’s price), underscoring material price variability that increases the probability of large moves and helps justify the elevated premium. The piece cautions that historical volatility and the provided price chart should be blended with fundamental analysis to judge whether the risk/reward of the April 2026 $16 put is appropriate for a seller.

In market context, mid‑afternoon S&P options flow showed a put:call ratio of 0.72 versus a long‑term median of 0.65, signaling somewhat elevated put demand and a cautious tone in options positioning. Given these signals, the trade is an income-oriented tactic that exposes a seller to pronounced downside risk in a highly volatile biotech name and does not provide participation in potential upside appreciation.

Key Decisions for Investors

• Only consider writing the April 2026 $16 put if you would be comfortable owning OLMA at a $13.40 effective basis and after completing company‑level fundamental due diligence
• If selling the put, size the position conservatively and treat the premium as compensation for elevated tail risk given OLMA's 123% trailing volatility rather than free upside exposure
• Monitor broad option flow and sentiment (the put:call ratio at 0.72 versus a 0.65 median) as a near‑term risk signal, and use stop/hedge triggers or cash‑secured structures to limit assignment and drawdown risk
• If the objective is upside participation rather than income, prefer owning shares instead of selling puts, since the put seller only benefits from premium unless assigned